Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 5

The benefits and risks of testosterone replacement therapy: a review

Authors Nazem Bassil, Saad Alkaade, John E Morley

Published Date June 2009 Volume 2009:5 Pages 427—448

DOI http://dx.doi.org/10.2147/TCRM.S3025

Published 11 June 2009

Nazem Bassil1, Saad Alkaade2, John E Morley1,3

1Division of Geriatric Medicine; 2Internal Medicine, Saint Louis University Health Sciences Center, St. Louis, Missouri, USA; 3GRECC, VA Medical Center, St. Louis, Missouri, USA

Abstract: Increased longevity and population aging will increase the number of men with late onset hypogonadism. It is a common condition, but often underdiagnosed and undertreated. The indication of testosterone-replacement therapy (TRT) treatment requires the presence of low testosterone level, and symptoms and signs of hypogonadism. Although controversy remains regarding indications for testosterone supplementation in aging men due to lack of large-scale, long-term studies assessing the benefits and risks of testosterone-replacement therapy in men, reports indicate that TRT may produce a wide range of benefits for men with hypogonadism that include improvement in libido and sexual function, bone density, muscle mass, body composition, mood, erythropoiesis, cognition, quality of life and cardiovascular disease. Perhaps the most controversial area is the issue of risk, especially possible stimulation of prostate cancer by testosterone, even though no evidence to support this risk exists. Other possible risks include worsening symptoms of benign prostatic hypertrophy, liver toxicity, hyperviscosity, erythrocytosis, worsening untreated sleep apnea or severe heart failure. Despite this controversy, testosterone supplementation in the United States has increased substantially over the past several years. The physician should discuss with the patient the potential benefits and risks of TRT. The purpose of this review is to discuss what is known and not known regarding the benefits and risks of TRT.

Keywords: hypogonadism, testosterone replacement therapy, erectile dysfunction, osteoporosis, cardiovascular disease

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Testosterone for the aging male; current evidence and recommended practice

Roger D Stanworth, T Hugh Jones

Clinical Interventions in Aging 2008, 3:25-44

Published Date: 26 March 2008

Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite

Takahiro Ueno, Hironori Tsuchiya, Maki Mizogami, Ko Takakura

Journal of Inflammation Research 2008, 1:41-48

Published Date: 13 November 2008

Drug design with Cdc7 kinase: a potential novel cancer therapy target

Masaaki Sawa, Hisao Masai

Drug Design, Development and Therapy 2008, 2:255-264

Published Date: 18 November 2008

Problems and barriers of pain management in the emergency department: Are we ever going to get better?

Sergey M Motov, Abu NGA Khan

Journal of Pain Research 2009, 2:5-11

Published Date: 9 December 2008

Tenofovir-associated bone density loss

Iwen F Grigsby, Lan Pham, Louis M Mansky, et al

Therapeutics and Clinical Risk Management 2010, 6:41-47

Published Date: 24 December 2009

Acute pain management in children

Susan T Verghese, Raafat S Hannallah

Journal of Pain Research 2010, 3:105-123

Published Date: 15 July 2010

Usefulness of serum mass spectrometry to identify women diagnosed with higher grades of cervical intraepithelial neoplasia may differ by race

Matthews R, Azuero A, Asmellash S, Brewster E, Partridge EE, Piyathilake CJ

International Journal of Women's Health 2011, 3:185-192

Published Date: 12 July 2011

Newer agents in antiplatelet therapy: a review

Yeung J, Holinstat M

Journal of Blood Medicine 2012, 3:33-42

Published Date: 25 June 2012